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Although white matter hyperintensities (WMH), markers of cerebral small vessel disease
(SVD), are believed to generally increase over time, some studies have shown
sharp decreases after therapeutic intervention, suggesting that WMH progression
may be more dynamic than previously thought. Our primary goal was to examine
dynamic progression of WMH in a real-world sample of Alzheimer’s disease (AD)
patients and normal elderly (NC), with varying degrees of SVD. WMH volumes
from serial magnetic resonance imaging (MRI; mean = 1.8 years) were measured
from NC (n = 44) and AD patients (n = 113) with high and low SVD burden.
Dynamic progression for each individual was measured using spatial overlap
images to assess shrinkage, growth, and stable WMH volumes. Significant group
differences were found for shrinkage (p < 0.001), growth (p < 0.001) and stable
(p < 0.001) WMH, where the AD high SVD group showed the largest changes
relative to low SVD and NC. Our results suggest spatial progression measured
at the individual patient level may be more sensitive to the dynamic nature of
WMH.
Keywords: Alzheimer’s disease, white matter hyperintensities, small vessel disease, aging, dementia, longitudinal
progression
INTRODUCTION
Recent advances in neuroimaging techniques have allowed for the volumetric quantification of
white matter hyperintensities (WMH) of presumed vascular origin, a radiological biomarker
of cerebral small vessel disease (SVD; Wardlaw et al., 2013) commonly visualized on T2-weighted
(T2), proton density (PD), and fluid-attenuated inversion recovery (FLAIR) magnetic resonance
imaging (MRI; Pantoni, 2010). The longitudinal progression of WMH have been previously
associated with vascular risk factors such as hypertension (Wolfson et al., 2013) and diabetes
(Taylor et al., 2003), aging (Vannorsdall et al., 2009), decreased gait performance (Silbert
et al., 2008), cognitive decline (Longstreth et al., 2005; Kramer et al., 2007; Debette et al., 2011),
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and brain atrophy (Schmidt et al., 2005), as well as
Alzheimer’s disease (AD) pathology at post-mortem
(Erten-Lyons et al., 2013).
While it is generally accepted that WMH typically increase
with aging and cerebrovascular disease progression, the
estimated growth rates often vary between studies. Among
the progression studies with quantitative WMH volumetrics
producing continuous measures, baseline to follow-up imaging
show increased WMH mean/median volumes ranging from
0.74 cc (∼4 years) to 4.6 cc (∼3.6 years) in normal elderly (NC)
cohorts (Kloppenborg et al., 2014).
However, there is some recent evidence to suggest that
in some cases, WMH burden may appear stable, with some
studies even demonstrating regression or decreased WMH
volume over time. Although early reports of this phenomenon
were attributed to measurement error (Schmidt et al., 2003;
Sachdev et al., 2007), recent radiological case reports have
shown WMH regression in patients after cerebral infarction
and ischemic stroke (Moriya et al., 2009; Durand-Birchenall
et al., 2012; Cho et al., 2015), liver transplantation and improved
hepatic encephalopathy treatment (Mínguez et al., 2007; Rovira
et al., 2007), and carotid artery stenting (Yamada et al., 2010).
Moreover, there is some evidence to suggest that drug treatments
may decrease or slow the progression of WMH (Mok et al.,
2009), leading some clinical trials to implement WMH burden
as a neuroimaging outcome measure (Dufouil et al., 2005; White
et al., 2013).
These previous findings suggest that WMH progression
may be more dynamic than previously understood. In this
study, we implement an imaging-based method to quantify the
dynamic progression of WMH which allows for the spatial
estimation of shrinking, growing, and stable WMH, at the
individual patient level. We examined dynamic progression
of WMH on a sample of NC participants (n = 44), and a
real-world sample of AD patients (n = 113) with high and
low WMH burden (Ramirez et al., 2015). Additionally, we
contrasted these results with those obtained using the more
conventional approach of just comparing baseline to follow-up
net volumes.
MATERIALS AND METHODS
Participants
Participants were sampled from the Sunnybrook Dementia
Study (ClinicalTrials.gov NCT 01800214), an ongoing
longitudinal study conducted at the Linda C. Campbell Cognitive
Neurology Research Unit, Hurvitz Brain Sciences Program at the
Sunnybrook Research Institute, and the University of Toronto,
Canada. NC participants (n = 44) met strict criteria that included
pre-screening and neuropsychological test performance that
was within normal limits for their age and education levels.
All AD participants (n = 113) met National Institute of
Neurological and Communicative Disorders and Stroke—AD
and Related Disorders Association criteria (McKhann et al.,
2011) probable/possible AD. Probable AD included patients
with none to mild WMH burden (AD low SVD, WMH < 3.5
cc: n = 56), and possible AD included patients with moderate to
severe WMH burden (AD high SVD, WMH > 3.5 cc: n = 57).
Although our AD high SVD group included patients with
severe WMH burden, this sample had no evidence of any
additional clinical criteria such as stroke temporally related to
cognitive impairment, multiple or extensive infarcts, features
of dementia with Lewy bodies, or other significant co-morbid
disease that could substantially affect cognition (McKhann
et al., 2011). Exclusion criteria included neurological diseases
other than dementia, history of significant head trauma,
tumors, normal pressure hydrocephalus, psychotic disorders
unrelated to dementia, psychoactive substance abuse, and major
depression.
All participants underwent a standardized comprehensive
clinical evaluation and consented to neuropsychological testing,
standardized brain MRI, and consented to the use of their data
for research purposes. Research was ethically conducted and
approved by the Sunnybrook Research Ethics Board.
MRI Acquisition
All brain imaging was acquired on a 1.5T GE Signa system
(Milwaukee, WI, USA) with the following protocol: a
T1-weighted axial 3D spoiled gradient recalled (SPGR):
Echo Time (TE) = 5 ms, Repetition Time (TR) = 35 ms,
Number of Averages (NEX) = 1, flip angle = 35◦, Field Of View
(FOV) = 22 cm, in-plane voxel size = 0.86 × 0.86 mm, slice
thickness range: 1.2–1.4 mm and an interleaved PD/T2-weighted
axial dual-echo spin echo: TE = 30/80 ms, TR = 3000 ms,
NEX = 0.5, flip angle = 90◦, FOV = 20 cm, in plane voxel
size = 0.78 × 0.78 mm, slice thickness = 3 mm. The mean
interscan interval (ISI) between baseline and follow-up scan was
approximately 2 years (Table 1).
Tissue Quantification
Tissue quantification was accomplished using in-house
segmentation tools (www.sabre.brainlab.ca) that yielded
an individualized volumetric profile of brain tissue and
volumetric imaging markers of SVD. Baseline and follow-up
volumes for gray matter (GM), white matter (WM), sulcal
cerebrospinal fluid (sCSF), and ventricular CSF (vCSF)
were obtained using a local histogram-based automatic
segmentation tool (Kovacevic et al., 2002). Baseline and
follow-up volumes for SVD markers, such as WMH and
cystic fluid-filled lacunar-like infarcts or ‘‘black holes’’ (BH),
were obtained using a semi-automatic tri-feature (T1/PD/T2)
segmentation algorithm called Lesion Explorer (Ramirez
et al., 2011, 2014). Baseline head size volumes were measured
by the total intracranial capacity (TIC), which included all
supratentorial brain matter and CSF voxels. Baseline global
brain atrophy was assessed by the Brain Parenchymal Fraction
(BPF) which was calculated on an individual basis as follows:
BPF = (GM +WM +WMH)/TIC.
WMH Progression Volumetrics
Volumetric data was generated using the conventional method
by calculating the net change in total WMH volume from
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TABLE 1 | Demographics and raw volumetrics for NC, AD low SVD and AD
high SVD groups.
NC AD low SVD AD high SVD P
(n = 44) (n = 56) (n = 57)
Demographics
Age, years (Baseline) 69.4 (7.0) 67.9 (8.0) 74.3 (8.3) ∗∗∗
Sex, n (%) male 19.0 (43.2) 28.0 (50.0) 22.0 (38.6) ns
Education, years 15.7 (2.7) 13.6 (3.5) 12.9 (3.5) ***
Interscan Interval, years 2.0 (1.2) 1.8 (1.1) 1.7 (0.8) ns
MMSE/30 (Baseline) 28.9 (1.3) 23.9 (3.3) 22.8 (4.3) ∗∗∗
MMSE/30 (Follow-up) 28.6 (1.2) 21.4 (5.8) 20.3 (6.2) ∗∗∗
Baseline volumes
TIC 1216.6 (126.8) 1189.3 (128.4) 1191.7 (143.5) ns
BPF, % (Baseline) 79.2 (3.5) 74.4 (4.5) 73.7 (3.6) ∗∗∗
WMH (Baseline) 4.4 (5.6) 1.3 (0.9) 14.0 (13.7) -
WMH (Follow-up) 5.1 (6.7) 1.7 (1.3) 15.7 (13.5) -
Volume change
(Follow-up - Baseline)
WMH difference 0.8 (2.0) 0.3 (1.1) 1.7 (5.1) ns
vCSF difference 2.5 (2.2) 7.2 (7.0) 8.4 (7.2) ∗∗∗
Dynamic volume
change (Spatial)
WMH shrink 1.3 (1.2) 0.7 (0.5) 3.8 (3.3) ∗∗∗
WMH grow 2.1 (2.3) 1.1 (0.9) 6.3 (4.3) ∗∗∗
WMH stable −0.6 (21.6) 0.5 (0.4) 9.3 (11.0) ∗∗∗
Data are presented as Mean (SD). Raw volumes are presented for transparency,
statistical analyses were performed on normalized data. Volumetrics are reported in
cubic centimeters (cc). ∗∗∗p < 0.001. NC, normal control; AD, Alzheimer’s disease;
SVD, small vessel disease; MMSE, mini mental state exam; TIC, total intracranial
volume; BPF, brain parenchymal fraction; WMH, white matter hyperintensity; vCSF,
ventricular cerebrospinal fluid.
baseline to follow-up (total volume change = follow-up
− baseline) for comparison with our dynamic progression
method.
For our dynamic progressionmethod, we used spatial location
to gain more information about the potential dynamic nature
of WMH. Baseline and follow-up T1 MRIs were transformed
into each individual’s intermediate space using linear registration
(FSL’s ‘‘FLIRT’’, 6◦ of freedom; Jenkinson et al., 2012). This was
accomplished by registering each baseline T1 image to follow-
up using ‘‘FLIRT’’ and then using the ‘‘avscale’’ command to
generate forward and backward halfway transformations. This
half transformation was then applied to each baseline and follow-
up image to create an intermediate image for both time points,
which was then averaged to create one image that represented
both baseline and follow-up in an intermediate space.
Once the intermediate T1 was generated, we registered
WMH and vCSF segmentations for baseline and follow-
up to each individual’s intermediate space. We then used
‘‘fslmaths’’ to create spatial difference/overlap masks between
baseline and follow-up. Spatial change in WMH included:
shrinking (WMH present in baseline but not in follow-
up), growing (WMH not present in baseline but present
in follow-up), as well as stable WMH (present in both
baseline and follow-up; Figure 1). Additionally, WMH voxels
that fell within the ventricles were masked out to account
for ventricular expansion into pre-existing WMH voxels
(Figure 2).
Statistical Analysis
Statistical analyses were performed on a PC using IBM SPSS
Statistics (version 22). AD patients were sub-divided into AD low
SVD (n = 56) and AD high SVD (n = 57) groups based on the
median split of WMH at baseline (Behl et al., 2007; McNeely
et al., 2015). Multivariate analysis of covariance (MANCOVA)
were performed to examine potential differences in basic
demographics and baseline characteristics (age, sex, education,
ISI, Mini Mental State Exam (MMSE), TIC, vCSF difference
and BH difference), secondary variables of interest (BPF, GM
difference and WM difference), and the primary between
group analyses for dynamic progression of WMH (i.e., shrink,
grow, stable, and total volume). Bonferroni corrected pairwise
comparisons were conducted post hoc. Due to the commonly
observed skewed distribution of SVD imaging markers (DeCarli
et al., 2005; Barnes et al., 2013), WMH change volumes were log
transformed to allow for parametric testing. Baseline TIC was
used to account for variations in head size, baseline vCSF and
BPF were included to account for brain atrophy, and baseline
MMSE (Folstein et al., 1975) scores were included to account for
disease severity.
RESULTS
Demographic and volumetric data are summarized on Table 1.
Age (p < 0.001), education (p < 0.001), and MMSE at
baseline and follow-up (p < 0.001) were found to be
significantly different between groups. Head-size (TIC), sex,
and ISI were not significantly different between groups and
were subsequently removed as covariates in further analyses. All
subsequent analyses were adjusted for baseline age, education,
disease severity, atrophy, and incidental infarcts. Significant
between group differences were demonstrated in baseline BPF
measures (p < 0.001), GM change (p < 0.001), WM change
(p < 0.001), and vCSF change (p < 0.001). Interestingly, the
conventional method yielded baseline to follow-up total net
WMH volume changes that were not significantly different
between groups (Table 1: ‘‘Volume change’’, Figure 3: ‘‘1 Total
Volume’’).
However, significant between group differences were
demonstrated using dynamic progression of WMH metrics:
WMH shrinkage (p < 0.001), WMH growth (p < 0.001), and
stable WMH (p < 0.001). Bonferroni corrected post hoc tests
revealed that dynamic progression of WMH was significantly
different between all groups, where the AD high SVD group had
significantly more shrinkage, growth, and stable WMH volumes
than NC (all, p < 0.001) and AD low SVD groups (all, p < 0.001;
Figure 3).
DISCUSSION
Our main findings suggest that WMH progression may be
more dynamic than previously thought. Specifically, AD patients
with significant radiological signs of cerebral SVD pathology at
baseline exhibited more dynamic progression of WMH over a
2 year period, when compared to AD patients with minimal SVD
burden and their NC counterparts.
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FIGURE 1 | Baseline (left) and follow-up (right) MRIs were half transformed into intermediate space (middle) using linear registration (FLIRT). Shrinking
(yellow), growing (blue) and stable (purple) white matter hyperintensities (WMH) spatial segmentations are displayed in intermediate space for a 71 year old female
with Alzheimer’s disease (AD). Net change in WMH total volume from baseline to follow-up was −1.5 cc. However, when considering dynamic progression based on
spatial information: shrinking WMH = −8.2 cc, growing WMH = +6.3 cc, and stable WMH = 32.4 cc.
FIGURE 2 | Two year ventricular expansion in a 60 year old man living with AD. Baseline vCSF = 83.6 cc, follow-up vCSF = 119.0 cc. Green indicates baseline
vCSF voxels, pink indicates follow-up (right) and growth (middle). WMH within vCSF growth regions were subsequently removed to account for ventricular expansion.
Progression rates of WMH volumes from serial MRI studies
vary considerably, however, the overall net volume change results
in our study were within the range of values previously reported
in the literature (see Table 2; Garde et al., 2005; Schmidt
et al., 2005; Kramer et al., 2007; Silbert et al., 2008; Marquine
et al., 2010; Wolfson et al., 2013). Interestingly, the largest net
volume increase of WMH in our study was observed in AD
patients with high SVD burden at baseline, which likely reflects
previous reports that demonstrate how baseline WMH burden
can significantly predict higher progression rates (Prins and
Scheltens, 2015).
Despite these reports of overall net increases of WMH
volume over time, some studies have demonstrated differential
progression rates spatially across various brain regions, and
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TABLE 2 | Summary of serial MRI studies examining WMH change over time.
Volume
Publication n Study Baseline age (y) Sample Baseline Follow-up Difference* Mean ISI
Current study
Ramirez et al. (2015) 44 Sunnybrook Dementia
Study, Canada
69.4 ± 7.0 Normal elderly
controls
4.4 (5.6) 5.1 (6.7) +0.8 (2.0) 2.0 y
Ramirez et al. (2015) 56 Sunnybrook Dementia
Study, Canada
67.9 ± 8.0 AD patients with
low SVD burden
1.3 (0.9) 1.7 (1.3) +0.3 (1.1) 1.8 y
Ramirez et al. (2015) 57 Sunnybrook Dementia
Study, Canada
74.3 ± 8.3 AD patients with
high SVD burden
14.0 (13.7) 15.7 (13.5) +1.7 (5.1) 1.7 y
Population studies
Wolfson et al. (2013) 67 University of Connecticut
Health Center, USA
81.7 ± 3.9 Community
dwelling elderly
1.0 1.7 +0.7 4.0 y
Garde et al. (2005) 26 Danish Glostrup
1914 cohort
80.7 ± 0.4 Cohort study 4.7 9.3 +4.6 3.6 y
Marquine et al. (2010) 110 Duke University Medical
Center, USA
70.7 ± 5.6 Normal elderly
controls
4.9 6.1 +1.2 2.0 y
Kramer et al. (2007) 50 Multi-center California,
USA
73.9 y ± 6.6 Healthy elderly
controls
8.0 10.4 +2.4 3.7 y
Schmidt et al. (2005) 292 Austrian Stroke Prevention
Study (3 y)
60.2 ± 6.3 Community
dwelling elderly
1.3 1.92 +0.6 3.0 y
Schmidt et al. (2005) 243 Austrian Stroke Prevention
Study (6 y)
60.2 ± 6.3 Community
dwelling elderly
1.4 2.7 +1.4 6.0 y
Cho et al. (2015) 100 Seoul St. Mary’s Hospital,
Korea (progress, n = 32)
67.5 ± 11.8 Ischemic stroke
patients
2.8† 6.1† +3.3 2.8 y
Cho et al. (2015) 100 Seoul St. Mary’s Hospital,
Korea (regress, n = 14)
67.5 ± 11.8 Ischemic stroke
patients
2.8† 0.9† −1.9 2.1 y
Silbert et al. (2008) 104 Oregon Brain Aging Study 85.1 ± 5.6 Healthy community
wilunteers
9.7 14.1 +4.4 9.1 y
Case reports
Rovira et al. (2007) 27 Pre-post liver transplant 55 Cirrhosis patients 1.3† 0.7† −0.6 9 m
Durand-Birchenall et al. (2012) 1 Post secondary stroke
prevention
69 Lacunar stroke 9.2 4.5 −4.7 6 m
Mínguez et al. (2007) 1 Pre-post intervention
(neomycin)
70 Hepatic
encepalopathy
(hep C)
7.5 2.0 −5.5 6 m
Mínguez et al. (2007) 1 Pre-post intervention
(neomycin)
65 Hepatic
encepalopathy
(alcoholic cirrhosis)
25.9 16.6 −9.3 1 m
Mínguez et al. (2007) 1 Pre-post intervention
(neomycin)
73 Hepatic
encepalopathy
(hep C cirrhosis)
18.6 10.4 −8.2 6 m
*Estimated change based on reported means at baseline and follow-up. †Median. Abbreviations: ISI, interscan interval; y, years; m, months.
even regression or decreases, providing early support for
the potential dynamic nature of WMH. When the spatial
distribution of WMH have been considered, differential
progression rates have been shown in the periventricular
compared to deep white brain regions (van den Heuvel
et al., 2004; Sabayan et al., 2015). Additionally, significant
WMH regression and signal attenuation has also been
previously demonstrated in radiological case reports with
pre- and post-therapeutic intervention imaging (Mínguez
et al., 2007; Rovira et al., 2007; Durand-Birchenall et al.,
2012).
Moreover, a recent serial MRI study performed on ischemic
stroke patients demonstrated both progression and regression,
with WMH regression observed in 21.5% of stroke patients
(Cho et al., 2015). These findings are particularly important
in individual cases where there are signs of simultaneous
progression (growing), regression (shrinking), and stable WMH,
as demonstrated in our study. The loss of information from
baseline to follow-up from volumetric averaging can further be
reflected in our group analysis, where the conventionalWMHnet
volume change between groups was non-significant but dynamic
progression rates were.
In light of the commonly accepted view that the pathogenesis
and clinical characteristics of ‘‘WMH of presumed vascular
origin’’ can be attributed to a set of heterogeneous and
complex etiologies associated with cerebral SVD (Gouw
et al., 2011), our findings provide further support for the
dynamic nature of the underlying pathology that is reflected
by these radiological entities. Although poorly understood,
there is some evidence to suggest that a common substrate
of diffuse WMH in the periventricular regions of the
brain may reflect a form of venous stenosis (Moody et al.,
1995; Black et al., 2009; Pantoni, 2010). Early findings
from imaging-pathology case studies suggest that the
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FIGURE 3 | Dynamic changes in WMH volume over a mean interscan
interval (ISI) of 2 years for NC, AD low small vessel disease (SVD), and
AD high SVD groups. P values represent significant differences between all
diagnostic groups, based on estimated marginal means, accounting for
baseline age, years of education, mini mental state exam (MMSE), and vCSF.
confluent periventricular WMH may reflect edema related
to collagenosis of the periventricular deep medullary veins
(Gao et al., 2014).
Fluid from chronic edema resulting from increased blood-
brain barrier permeability (Farrall and Wardlaw, 2009),
intraparenchymal venous abnormalities (Brown et al.,
2009), and/or disturbances in interstitial fluid circulation
(Weller et al., 2009), may also explain the dynamic
shrinkage and growth of WMH that was demonstrated
in our study, as edematous fluid has been known to
partially resolve after time has elapsed (or therapeutic
intervention is performed). Thus, edema visualized as
WMH on MRI may be an indicator of complex multiple
underlying pathologies that include venous collagenosis
and/or arteriolosclerosis. These chronic SVD pathologies may
result in increased blood-brain barrier leakage and interstitial
fluid accumulation due to increased venous pressure and
decreased fluid drainage along the perivascular channels
as a consequence of vascular rigidity and reduced vascular
pulsation. These proposed multi-factorial etiologies make it
challenging to attribute regression to ‘‘recent’’ vs. ‘‘older’’
lesions. However, collagenosis and/or arteriolosclerosis are
insidious chronic processes, which could gradually lead
to increased fluid accumulation, but also allows time for
fluid resolution, where WMH regression may reflect the
rate of resolution (clearance or drainage of fluid) when it
is temporarily greater than the rate of fluid accumulation.
Moreover, this dynamic process of fluid accumulation
and clearance may also be modulated by other factors,
such as blood pressure (Hauser et al., 1988), during image
acquisition.
Additionally, there is some evidence to suggest that a
proportion of focal infarcts may resemble and/or distort WMH
volumes due to their similarity in signal intensity (Wang et al.,
2012). As incomplete and partially cavitated lacunar infarcts
and acute small subcortical strokes tend to resemble WMH,
when measured longitudinally, many of these lesions (94%) have
been shown to completely or incompletely cavitate, reduce in
diameter, and/or disappear (5%) on follow-up imaging (Lammie
et al., 1998; Potter et al., 2010; Loos et al., 2012). This process may
also partially account for the dynamic progression findings in our
study.
One limitation of our study is the lack of additional
time points for neuroimaging measures. As the Sunnybrook
Dementia Study is a longitudinal observational study,
additional follow-up scans for each individual will become
available for future analysis to provide a more accurate
picture regarding the dynamic changes of WMH in a
real-world sample of dementia patients with varying
degrees of comorbid SVD pathology (Ramirez et al., 2015).
Additionally, as both a benefit and a caveat, the ability
of our method to spatially account for vCSF expansion is
particularly relevant in studies on aging and dementia since
ventricle size is an important indicator of brain atrophy,
commonly observed in AD-related neurodegeneration and
normal aging (Nestor et al., 2008; Apostolova et al., 2012;
Madsen et al., 2015). Unfortunately, while this dynamic
feature in our method accounts for ventricular expansion,
it may also introduce potential error, as baseline WMH
voxels which overlay onto newly labeled vCSF voxels
are removed due to ventricular expansion at follow-up.
Should the baseline volumes of periventricular WMH
that eventually become engulfed into the ventricular
compartment be quantified as a separate unique volume?
To our knowledge, previous studies have not considered
this, although many studies (including this one) include
ventricular volume as a covariate to account for medial
atrophy.
Future work examining dynamic progression with spatial
information from both WMH and ventricular expansion would
be beneficial when examining vascular co-pathology in AD
and neurodegenerative populations. Future therapeutic strategies
that target cerebrovascular contributions to AD dementia, such
as the use of anti-hypertensive treatments (Dufouil et al.,
2009; Jochemsen et al., 2012, 2015; White et al., 2013), may
be particularly interested in the shrinkage, growth, and stable
metrics examined in our study. Although several complex
statistical modeling approaches have been proposed to analyze
longitudinal structural data (McArdle et al., 2004; Grimm et al.,
2012), our approach is relatively simple by comparison and
can be implemented into any serial imaging study in parallel
with the conventional baseline to follow-up net volume change
approaches.
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CONCLUSION
The findings from this study suggest that individual WMH
volume changes are more dynamic than previously thought. The
simultaneous shrinkage and growth of WMH was particularly
evident in AD patients with significant signs of cerebral
SVD. Given that our dynamic progression measures provided
information that was above and beyond the standard net volume
change, our results suggest that the measurement of dynamic
volumetrics for WMH may be particularly valuable in clinical
trials that use imaging outcome measures and may further
elucidate the complex pathogenesis and longitudinal progression
of this radiological entity we commonly refer to as WMH of
presumed vascular origin.
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